Open AccessAn in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
Author(s) -
Natalia Blanco,
Betsy Foxman,
Anurag Malani,
Min Zhang,
Seth T. Walk,
Alexander H. Rickard,
Marisa C. Eisenberg
Publication year - 2017
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0182815
Subject(s) - clostridium difficile , vancomycin , spore , regimen , medicine , in silico , germination , spore germination , antibiotics , transmission (telecommunications) , biology , microbiology and biotechnology , bacteria , staphylococcus aureus , biochemistry , genetics , botany , electrical engineering , engineering , gene
Background Clostridium difficile infection (CDI) is a significant nosocomial infection worldwide, that recurs in as many as 35% of infections. Risk of CDI recurrence varies by ribotype, which also vary in sporulation and germination rates. Whether sporulation/germination mediate risk of recurrence and effectiveness of treatment of recurring CDI remains unclear. We aim to assess the role of sporulation/germination patterns on risk of recurrence, and the relative effectiveness of the recommended tapered/pulsing regimens using an in silico model. Methods We created a compartmental in-host mathematical model of CDI, composed of vegetative cells, toxins, and spores, to explore whether sporulation and germination have an impact on recurrence rates. We also simulated the effectiveness of three tapered/pulsed vancomycin regimens by ribotype. Results Simulations underscored the importance of sporulation/germination patterns in determining pathogenicity and transmission. All recommended regimens for recurring CDI tested were effective in reducing risk of an additional recurrence. Most modified regimens were still effective even after reducing the duration or dosage of vancomycin. However, the effectiveness of treatment varied by ribotype. Conclusion Current CDI vancomycin regimen for treating recurrent cases should be studied further to better balance associated risks and benefits.